Spring­Works fix­es 'mi­nor da­ta han­dling er­ror' af­ter March Form 483 for tri­al site linked to up­com­ing PDU­FA

The FDA is­sued Spring­Works Ther­a­peu­tics a Form 483 on March 31, say­ing that the com­pa­ny’s own clin­i­cal tri­al pro­to­cols were not fol­lowed.

But Spring­Works COO Badred­din Edris told End­points News in a phone in­ter­view on Mon­day that “it was a mi­nor da­ta han­dling er­ror on an ex­plorato­ry end­point that was cor­rect­ed with­in a week in March and re­sult­ed in no im­pact on the da­ta” that formed the ba­sis of the com­pa­ny’s ap­pli­ca­tion for its first “pipeline-in-a-prod­uct” on­col­o­gy treat­ment, the oral gam­ma sec­re­tase in­hibitor, dubbed nirogace­s­tat, or Og­siveo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER